Georgiamune Inc.: Green Light from US FDA and $75M Series A Funding Propel Next-Gen Breakthroughs

Gaithersburg, MD, August 9, 2023 (PRNewswire) -- Georgiamune Inc., a clinical-stage biotechnology has secured $75 million through a successful Series A financing round. This infusion of capital supports Georgiamune's ability to execute on its ability to make an impact on oncology and autoimmune diseases, firmly establishing the company as a promising force in the biotechnology landscape.

Read full article here.